Sökning: onr:"swepub:oai:DiVA.org:uu-305937" >
A case report of a ...
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
-
- Maleka, Aglaia (författare)
- Uppsala universitet,Experimentell och klinisk onkologi,Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden.
-
- Åström, Gunnar (författare)
- Uppsala universitet,Radiologi,Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden.
-
- Bystrom, P. (författare)
- Novartis Sverige AB, Kemistvagen 1, S-18379 Taby, Sweden.
-
visa fler...
-
- Ullenhag, Gustav J. (författare)
- Uppsala universitet,Experimentell och klinisk onkologi,Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden.
-
visa färre...
-
(creator_code:org_t)
- 2016-08-12
- 2016
- Engelska.
-
Ingår i: BMC Cancer. - : Springer Science and Business Media LLC. - 1471-2407. ; 16
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://bmccancer.bi...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM. Case presentation: We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a BRAFV600E mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a week and she experienced a progression free survival of four months. Conclusions: To our knowledge, this is the first described case of response to vemurafenib treatment in a patient with ocular melanoma.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- BRAF inhibitor
- BRAF mutation
- Conjunctival malignant melanoma
- Ocular melanoma
- Vemurafenib
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas